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It is well known that chronic hyperglycemia is a major contributor to microvascular
complications. Diabetic nephropathy is one of the most serious microvascular
complications and leading cause of mortality and morbidity in diabetic patients.
There are several mechanisms of diabetic nephropathy including the activation of
protein kinase C (PKC), increased advanced glycosylation end products, the
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Purpose: The vascular endothelial growth factor (VEGF) expression of podocyte
is one of the well-known major factors in development of diabetic nephropathy. In
this study, we investigated the effects of aldose reductase inhibitor, fidarestat on
diabetic nephropathy, and renal VEGF expression in a type 1 diabetic rat model.
Materials and Methods: Twenty four Sprague-Dawley male rats which were
performed intraperitoneal injection of streptozotocin and normal six rats were
divided into four groups including a normal control group, untreated diabetic control
group, aldose reductase (AR) inhibitor (fidarestat, 16 mg ˙ kg
-1
˙ day
-1) treated
diabetic group, and angiotensin receptor blocker (losartan, 20 mg ˙ kg
-1
˙ day
-1)
treated diabetic group. We checked body weights and blood glucose levels
monthly and measured urine albumin-creatinine ratio (ACR) at 8 and 32 weeks.
We extracted the kidney to examine the renal morphology and VEGF expressions.
Results: The ACR decreased in fidarestat and losartan treated diabetic rat groups
than in untreated diabetic group (24.79 ± 11.12, 16.11 ± 9.95, and 84.85 ± 91.19, p
< 0.05). The renal VEGF messenger RNA (mRNA) and protein expression were
significantly decreased in the fidarestat and losartan treated diabetic rat groups than
in the diabetic control group. Conclusion: We suggested that aldose reductase
inhibitor may have preventive effect on diabetic nephropathy by reducing renal
VEGF overexpression.
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upregulation of cytokines and growth factors, and activa-
tion of rennin angiotensin system.1-4 These mechanisms are
known to participate in the increase of renal vascular endo-
thelial growth factor (VEGF) production.5-9
It has been reported that VEGF is a mitogenic factor for
vascular endothelial cells and involved in vasopermea-
bility.10 Recent data showed that VEGF gene expression in-
creased in diabetic kidneys and could be reduced by VEGF
antibodies or angiotensin receptor blockers (ARB).6,11-14 So,
it has been considered that VEGF may be an important
factor in the progression of diabetic nephropathy and regula-
tion of VEGF expression is a potential therapeutic target
for treatment of diabetic nephropathy. 
Intracellular hyperglycemia activates the polyol pathway,
which is one of the pathogenic pathways involved in dia-
betic microvascular complications.15,16 Aldose reductase
(AR) is the key enzyme that catalyzes nicotinamide adenine
dinucleotide phospate (NADPH) in the polyol pathway,
which eventually leads to the reduction of glucose to sorbi-
tol.15 It was reported that increased AR activity derived
from hyperglycemia could induce retinal VEGF over-
expression and  administration of fidarestat, a highly
specific AR inhibitor (ARI), could ameliorate retinal VEGF
expression in a diabetic rat model.17
In this study, we investigated the effects of ARI on
diabetic nephropathy and renal VEGF expression in a type
1 diabetic rat model and compared the effects with angio-
tensin receptor blocker which could reduce renal VEGF
expression. 
Animals
Eight-week-old male Sprague-Dawley rats weighing 200-
250 g were purchased. At nine weeks of age, diabetes was
induced by a single injection of streptozotocin (70 mg/kg
body weight) into the intraperitoneum. One week later, rats
with glucose levels higher than 200 mg/dL were consi-
dered diabetes mellitus. The experimental rats were divided
into four groups, including a normal control group (CON,
n = 6), a diabetic control group (DM, n = 10), a fidarestat
treated diabetic group (DM + ARI, 16 mg ˙ kg
-1
˙ day
-1, n =
10), and an angiotensin II receptor blocker treated diabetic
group (DM + ARB, losartan, 20 mg ˙ kg
-1
˙ day
-1, n = 10) as
a positive control. Fidarestat was administered via a stan-
dard diet, while losartan was administered by orally through
a gavage tube from 9 to 32 weeks of age. 
We monitored body weights monthly and blood glucose
levels (Surestep®, Lifescan Inc., Milpitas, CA, USA) from
the tail vein weekly. Twenty four hours urine was collected
for assessment of albumin (Roche Molecular Biochemicals,
Indianapolis, IN, USA) and creatinine levels at 8 and 32
weeks of age.
Kidney extraction
At 33 weeks of age, rats were anesthetized with ketamine
hydrochloride (70 mg/kg) by intraperitoneal injection and
both kidneys were extracted. One kidney was preserved
using a quick freeze method with liquid nitrogen while the
contralateral kidney was fixed in 4% paraformaldehyde for
48 hours, and then embedded in paraffin for histological
examination and immunohistochemical staining of VEGF. 
Measurement of glomerular volumes and mesangial 
matrix index
Paraffin embedded tissues were cut into 5 µm thick sections
and stained with periodic acid-Schiff (PAS) stain. We
examined these sections with an optical microscope that
was equipped with a charge coupled device camera (Pulnix,
Sunnyvale, CA, USA) in order to obtain pictures of glo-
meruli, which were subsequently sent to a computer moni-
tor. We measured 40 glomerular areas per rat using an
image analysis system (GmbH, SIS, Minster, Germany).
In addition, we calculated glomerular volume by the
Weibel and Gomez formula:18 Glomerular volume (Gv) =
Area1.5×1.38/1.01 (1.38: shape coefficient, 1.01: size
distribution coefficient). 
Glomerular matrix index was assessed in 40 glomeruli
per each rat after locating the slices on the center of the
camera and scored as grade 0 to 4: grade 0, normal glome-
ruli; grade 1, mesangial expansion area up to 25%; grade
2, 25% to 50%; grade 3, 50% to 75%; grade 4, 75% to
100%; estimated and put into 0 to 4 scale.19 A kidney slide
was assessed 10 times. 
Calculation of optical density of VEGF 
After paraffin embedded tissues were cut into 5 µm-thick
slices, they were placed on slides and the paraffin was
removed in order to carry out immunohistochemical stain-
ing. Shortly after paraffin removal, the slides were trans-
ferred into a 10 mm/L citrated buffer solution (pH 6) and
washed with distilled water. The slides were then immersed
in a 0.05% H2O2-methanol solution for 15 minutes, and
were then placed in an anti-VEGF antibody solution (Santa
Cruz Biotechnology, Inc., California, CA, USA), which
was diluted 1 : 1000 at room temperature. The slides were
then processed with a biotinylated secondary antibody
using a Rat ABC staining system (Santa Cruz Biotech-
nology, Inc., California, CA, USA) and avidin-biotinpero-
xidase complex (ABC reagents). Finally, the slides were
incubated with peroxidase substrates, which included 0.05%
3, 3’-diaminobenzidine tetrahydrochloride (DAB).
We investigated the stained tissues using the same opti-
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cal microscope setup described above (Pulnix, Sunnyvale,
CA, USA). We measured the optical density of stained
VEGF using an image analysis system (GmbH, SIS,
Minster, Germany). 
RNA extraction and preparation of cDNA
Total RNA was isolated from the frozen kidney tissues
using TRIzol reagent (Invitrogen Life Technologies Inc.,
Gaithersburg, MD, USA) as described in the product ma-
nual; the amount of RNA obtained was determined by
spectrophotometry. A total of 1 µg of RNA was mixed with
500 µg/mL oligo d(T)15 primer, 200 U/mL of moloney
murine leukemia virus (MMLV) reverse transcriptase
(RT), 10 mM dNTPs, 40 U/µL RNase inhibitor, and
MMLV RT 5× buffer (Promega, San Luis Obispo, CA,
USA) to make a final reaction volume of 25 µL. The mix-
ture was incubated at 42˚C for 30 min and the reaction was
terminated by raising the temperature to 95˚C for 5 min.
Reverse transcriptase-polymerase chain reaction (RT-
PCR) reactions were carried out via automatic thermo-
cycling (MJ Mini Thermal Cycler, BIO-RAD, Hercules,
CA, USA). 
Real time RT-PCR for VEGF
Prepared complementary DNA (cDNA) and primer of rat
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or
VEGF were mixed with 10× QuantiTect Primer Assay
(Qiagen, Valencia, CA, USA) and a Syber Green RT-PCR
kit (Qiagen, Valencia, CA, USA). Samples were subjected
to real-time RT-PCR using a Roter-Gene RG-3000 cycler
(Corbett Research, Mortlake, NSW, Australia). The Syber
Green RT-PCR conditions were as follows: 15 sec at 94˚C,
30 sec at 58˚C, and 30 sec at 72˚C, with the total number of
cycles ranging from 40 to 45. Data was analyzed with the
software provided by Roter-Gene. Syber Green Ct values
were determined using GAPDH normalization. To avoid
contamination, all assays were performed according to
universal thermal cycling parameters and all experiments
were performed in triplicate.
Statistical analysis
All results are presented as means ± SD. Data was analyzed
using SPSS version 11. Statistical significance was evaluated
using analysis of variance (ANOVA) with Tukey’s post-
test (multiple comparisons). p values of less than 0.05 were
considered statistically significant. 
Clinical characteristics in experimental animals
At eight weeks of age, there was no difference in body
weight between the control and diabetic groups (all rats
had body weights of 200-250 g). However, body weights
were significantly lower in the diabetic control, as well as all
of the medication treated diabetic groups, when compared
with the normal control group at 32 weeks of age. Blood
glucose levels increased approximately 4 to 5 fold in dia-
betic rats compared with control rats. There were no statis-
tically significant differences between untreated diabetic
and ARI or ARB treated diabetic rats with respect to blood
glucose concentration (Table 1).
Changes of 24 urinary albumin levels and ACR
At 8 weeks of age, 24 hour urinary albumin excretion and
albumin creatinine ratios (ACR) were not different among
the experimental rat groups. At 32 weeks of age, a progres-
sive increase of 24 hour urinary albumin and ACR were
observed in all rat groups compared with those of the 8
weeks. In the fidarestat and losartan treated groups, 24
hour urinary albumin excretion and ACR were signifi-
cantly lower than that of the diabetic rat group at 32 weeks
(ACR: DM + ARI; 9.96 ± 10.68, DM + ARB; 6.61 ± 9.05,
DM; 84.85 ± 91.19 mg/gCr). The decrease of ACR was
approximately 64% of the ARI treated DM group and 81%
of the ARB treated DM group compared with the diabetic
control group (Table 2).
Glomerular volumes and glomerular matrix index
Although the calculated glomerular volumes did not show
significant differences among the experimental groups,
glomerualr mesangial expansion was observed in the DM
group compared with other groups in PAS staining of
glomeruli (Fig. 1). Also, glomerular matrix index (GMI)
RESULTS
Table 1. Body Weights (g) and Blood Glucose Levels (mg/dL) at 32 Weeks 
CON (n = 6) DM (n = 5) DM + ARI (n = 10) DM + ARB (n = 9)
Body weights 700.28 ± 67.45 480.00 ± 75.07* 503.00 ± 59.18* 445.20 ± 63.83*
Blood glucose 95.6 ± 8.31 436.4 ± 59.67* 462.3 ± 49.98* 411.9 ± 77.95*
CON, control; DM, diabetes; ARI, aldose reductase inhibitor; ARB, angiotensin II receptor blocker.
The body weights of diabetic rats were significantly reduced compared to the control rats. Blood sugar was also markedly increased in
diabetic rats compared to normal control rats, and ARI and ARB administration didn't have an effect on the reduction of blood sugar.
Data are mean ± SD.
*p < 0.05 compared with CON.
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scores significantly decreased in the CON group (1.05 ±
0.05) and all medication treatment groups (DM + ARI; 1.088
± 0.153, DM + ARB; 1.075 ± 0.175, p < 0.001 vs. DM
group) compared with the DM group (2.1 ± 1.122) (Fig. 2).
Renal VEGF expression
In the DM group, immunohistochemical stain for VEGF in
the kidney showed darker brown pigmentation than other
groups (Fig. 3). Compared with the CON group, the optical
density of immunohistochemical staining for renal VEGF
in the DM group significantly increased and restored in
ARI and ARB treated rat groups (Fig. 3). 
Renal VEGF mRNA expression 
For quantification of renal VEGF mRNA expression, we
examined real time RT-PCR. The VEGF/GAPDH ratio
was 8.32 fold in the DM group, 1.52 fold in the DM + ARI
group, and 1.35 fold in the DM + ARB group compared
with the CON group. The ARI treatment decreased VEGF
mRNA expression by 82% compared with the DM group.
Significant differences in VEGF mRNA expression bet-
ween the ARI and ARB treated diabetic groups were not
observed (Fig. 4). 
Table 2. Changes of 24 Hour Urinary Albumin (mg/day) and ACR (mg/mmol)
Albumin ACR
8th 32nd 8th 32nd
CON 197.43 ± 218.20 579.72 ± 229.31 3.78 ± 7.48 11.14 ± 10.5
DM 170.43 ± 264.17 1782.94 ± 1495.75* 4.64 ± 4.34 84.85 ± 91.19*
DM+ARI 174.68 ± 181.71 626.27 ± 128.33� 9.96 ± 10.68 24.79 ± 11.12�
DM+ARB 285.05 ± 375.59 330.19 ± 143.02� 6.61 ± 9.05 16.11 ± 9.95�
CON, control; DM, diabetes; ARI, aldose reductase inhibitor; ARB, angiotensin II receptor blocker; ACR, albumin creatinine ratio.
Urine albumin excretion and ACR significantly increased in 32-week-old diabetic control rats compared to the eight-week-old rats. ARI and
ARB treated diabetic rats showed that urine albumin excretion and ACR were significantly reduced compared to the diabetic control rats.
Data are presented as means ± SD.
*p < 0.05 compared with CON.
�p < 0.05 compared with DM.
Fig. 1. Representative examples of PAS staining of glomeruli are shown for (A) CON, (B) DM, (C) DM + ARI, and (D) DM + ARB. (E) is calculated glomerular volumes at
32nd week. The calculated glomerular volumes did not differ among the experimental groups. Scale bar, 100 µm.  CON, control; DM, diabetes; ARI, aldose reductase
inhibitor; ARB, angiotensin II receptor blocker.
Fig. 2. Comparison of glomerular matrix indices (GMI). Although calculated
glomerular volumes did not differ among the experimental groups, the
glomerular mesangium significantly expanded in untreated diabetic rats
compared to the control rats, and it was ameliorated by ARI and ARB
treatments. CON, control; DM, diabetes; ARI, aldose reductase inhibitor; ARB,
angiotensin II receptor blocker. *p < 0.05 compared with CON, �p < 0.05
compared with DM.
A B
C D E
In this study, we found that aldose reductase inhibitor, fida-
restat, could reduce the albumin excretion by ameliorating
the VEGF expression in streptozotocin-induced diabetic
rats as like angiotensin receptor blocker, losartan.
Diabetic nephropathy is the most serious complication
of diabetes, and is the most common cause of end-stage renal
disease. During the early phase of diabetic nephropathy,
glomerular hyperplasia and thickening of glomerular base-
ment membranes with mesangial protein accumulation may
appear.3 These processes could lead to glomerular hyper-
filtration and microalbuminuria initially, and eventually
progress to renal failure and end stage renal disease.20 Many
factors contributed to these processes such as advanced
glycation end products, PKC activation, transforming
growth factor-β, and other growth factors.2,11,21 In addition, it
has been demonstrated that AR activity increased in
diabetic nephropathy.22 There is a positive relationship
between the severity of glomerular structural changes and
the immunoreactivity of AR.23 Donnelly, et al. reported
that tolrestat could prevent glomerular hyperfiltration and
extracelluar matrix accumulation in streptozotocin-induced
diabetic rats.24 Furthermore, Isogai, et al.25 demonstrated
that epalrestat could rescue glomerular basement mem-
brane shrinkage and reduce urinary albumin excretion in a
diabetic rat model.
In this study, the glomerular volume was not different
among all experimental groups, but mesangial expansion
was observed in the diabetic control group compared with
the normal control and medication treated rat groups. This
data could be explained by glomerular sclerosis because
glomerular sclerosis might be derived from long term hyper-
glycemic conditions. However, we could suggest that fida-
restat could affect the renal structure by decreasing mesan-
gial expansion.
AR activity may induce diabetic nephropathy by several
mechanisms such as increased lipid peroxidation, depletion
of major nonenzymatic antioxidants, and downregulation
of superoxide dismutase activity.21,26-28 The polyol pathway
which is activated by hyperglycemic conditions may in-
crease the production of superoxide - and nicotinamide
adenine dinucleotide - induced reactive oxygen species
(ROS), and could enhance VEGF mRNA expression.29
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Fig. 4. Quantification of renal VEGF mRNA by real time RT-PCR. The VEGF /
GAPDH ratio in the diabetic control group increased compared to the normal
control rats. Treatment with ARI decreased VEGF mRNA expression. In
addition, the ARB treated diabetic group decreased VEGF mRNA expression.
However, there were no significant differences in VEGF mRNA expression
between the ARI and ARB treated diabetic groups. *p < 0.05 compared with
CON, �p < 0.05 compared with DM. VEGF, vascular endothelial growth factor;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; mRNA, messenger
RNA; RT-PCR, reverse transcriptase-polymerase chain reaction; CON, control;
DM, diabetes; ARI, aldose reductase inhibitor; ARB, angiotensin II receptor
blocker.
Fig. 3. Immunohistochemical staining for VEGF from (A) CON, (B) DM, (C) DM + ARI, (D) DM + ARB. Scale bar, 100 µm. (E) is optical density of the glomerular VEGF. The
optical density of immunohistochemical staining for VEGF in the diabetic control group increased significantly compared to the normal control group. Furthermore, the ARI
and ARB treated diabetic groups had significantly lower expression of VEGF than the diabetic control group. *p < 0.05 compared with CON, �p < 0.05 compared with DM.
VEGF, vascular endothelial growth factor; CON, control; DM, diabetes; ARI, aldose reductase inhibitor; ARB, angiotensin II receptor blocker.
A B
C D E
DISCUSSION
Various data has shown that VEGF expression is in-
creased in diabetic rat models and administration of anti-
VEGF antibodies to diabetic rats could suppress urinary
albumin excretion by reducing hyperpermeability, glome-
rular basement membrane thickness, and mesangial expan-
sion.12,13,30 There were many factors that could increase
VEGF levels. It is known that various cytokines and growth
factors including transforming growth factor-β, reactive
oxygen species, and activation of rennin-angiotensin system
could increase renal VEGF expression.1-4 Previously, we
demonstrated that diabetic nephropathy could be improved
by treatment of  theangiotensin receptor blocker by decrea-
sing renal VEGF expression.14 For these reasons, VEGF is
thought to be an important factor in the development of dia-
betic nephropathy.
In the present study, we showed that 24 hour urinary
albumin creatinine ratio (ACR) and renal VEGF expression
were significantly increased in diabetic rats and fidarestat
treatment could improve the diabetic nephropathy concor-
dance with decreasing renal VEGF expression similar to
losartan treatment. Our data could suggest that fidarestat
could improve diabetic nephropathy by reducing renal
VEGF expression. 
The first discovered aldose reductase inhibitor, tolrestat,
was withdrawn because of the side effects of hepatic nec-
rosis.31 In our experiment, the fidarestat feeding diabetic
rats all survived. In spite of our data, a safety profile should
be provided in future studies. 
In this study, losartan was used as a positive control. It
has been reported that VEGF expression could be inhibited
by treatment with ARB.14,32 Our data showed that the ability
of VEGF reduction did not distinguish between fidarestat
and losartan treated rat groups, indicating that fidarestat
could affect the prevention of diabetic nephropathy.  
In conclusion, our findings suggested that fidarestat
treatment could improve the diabetic nephropathy by reduc-
ing renal VEGF expression in type 1 diabetic rat model.
Further clinical studies should take place for the establish-
ment of fidarestat treatment in diabetic nephropathy. 
Fidarestat compound was kindly supported by Sanwa Kaga-
ku Kenkyusho Co., Ltd, Japan.
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